Asthma Triggers: Common Causes and How to Manage Airway Inflammation

An Airway That Overreacts

Approximately 25 million Americans have asthma — including more than 5 million children — making it one of the most common chronic respiratory conditions in the United States. Every year, asthma accounts for about 1.6 million emergency department visits and 3,500 deaths. Globally, the World Health Organization estimates that asthma affects 262 million people and caused 455,000 deaths in 2019.

The distinguishing feature of asthma is airway hyperresponsiveness: the bronchi and bronchioles react to stimuli that would not affect a person without asthma. This overreaction produces bronchoconstriction, mucosal edema, and excess mucus secretion — the triad that narrows airways and makes breathing difficult. The process is reversible, at least partially, which distinguishes asthma from chronic obstructive pulmonary disease (COPD).

The Underlying Physiology

Asthma involves two interrelated processes: acute bronchoconstriction and chronic airway inflammation. These processes reinforce each other.

In allergic (atopic) asthma — the most common form — sensitized mast cells and eosinophils in the airway wall release inflammatory mediators when the patient encounters an allergen. Histamine, leukotrienes, and prostaglandins cause smooth muscle contraction (bronchoconstriction) within minutes. This "early-phase response" produces the acute symptoms of wheezing, coughing, and shortness of breath.

Four to twelve hours later, a "late-phase response" brings an influx of eosinophils, T lymphocytes, and macrophages into the airway wall. This sustained inflammation causes mucosal swelling and increased mucus production. Over years, repeated inflammatory episodes cause structural changes — airway remodeling — including subepithelial fibrosis and smooth muscle hypertrophy, which can produce permanent airflow limitation.

Common Asthma Triggers

A trigger is any stimulus that provokes airway hyperresponsiveness in a person with asthma. Different patients respond to different triggers, and the same patient may react to multiple:

Allergenic Triggers

• Dust mites: Microscopic arachnids in bedding, carpets, and upholstery — the most common indoor allergen trigger globally
• Pet dander: Proteins in cat and dog skin flakes and saliva; cat allergen (Fel d 1) is particularly potent and spreads widely indoors
• Cockroach allergen: Strongly associated with asthma severity in urban populations
• Mold: Alternaria and Cladosporium species are the most commonly implicated outdoor molds; Aspergillus and Penicillium are common indoors
• Pollen: Tree, grass, and weed pollens trigger seasonal asthma exacerbations in sensitized individuals

Non-Allergenic Triggers

• Respiratory infections: Rhinovirus (common cold) is the most frequent asthma exacerbation trigger in both children and adults
• Exercise: Exercise-induced bronchoconstriction (EIB) occurs in 40–90% of asthma patients; cold, dry air worsens the response
• Air pollutants: Ozone, particulate matter (PM2.5), nitrogen dioxide, and sulfur dioxide all increase asthma exacerbation rates
• Occupational exposures: Isocyanates (polyurethane), flour dust, latex, and cleaning products cause occupational asthma
• Tobacco smoke: Both active smoking and secondhand smoke impair lung function and increase exacerbation frequency
• Aspirin and NSAIDs: Aspirin-exacerbated respiratory disease (AERD) affects approximately 10% of asthma patients
• Strong emotions and stress: Can alter breathing patterns and trigger bronchospasm

Asthma Classification by Severity

(FEV1 = forced expiratory volume in 1 second, measured by spirometry; classification per NAEPP Expert Panel Report 3.)

Diagnosis

Asthma diagnosis rests on a combination of characteristic symptoms and objective evidence of variable airflow obstruction. Key diagnostic steps include:

• Spirometry: Demonstrates obstruction (FEV1/FVC ratio <0.70) and reversibility (≥12% and 200 mL improvement in FEV1 after bronchodilator)
• Bronchoprovocation testing: Methacholine challenge identifies airway hyperresponsiveness in patients with normal spirometry
• Allergy testing: Skin prick tests or specific IgE blood tests identify sensitizing allergens
• Exhaled nitric oxide (FeNO): Elevated levels suggest eosinophilic airway inflammation
• Peak flow monitoring: Variability of ≥10–20% over time supports the diagnosis

The Step-Up Treatment Approach

(ICS = inhaled corticosteroids; LABA = long-acting beta-2 agonist; SABA = short-acting beta-2 agonist, e.g., albuterol.)

Biologic therapies targeting specific inflammatory pathways have transformed treatment for severe asthma. Monoclonal antibodies targeting IgE (omalizumab), IL-5 (mepolizumab, reslizumab, benralizumab), IL-4/IL-13 (dupilumab), and TSLP (tezepelumab) are now approved for add-on therapy in severe allergic or eosinophilic asthma. Tezepelumab, approved in 2021, reduces exacerbations across all asthma phenotypes, including non-eosinophilic disease.

Trigger Avoidance and Environmental Control

Pharmacological treatment is most effective when combined with trigger avoidance. Evidence-based environmental control measures include encasing mattresses and pillows in allergen-impermeable covers, washing bedding weekly in hot water (≥130°F), using HEPA air filtration, eliminating indoor mold sources, and removing pets from the bedroom. For occupational asthma, removal from exposure is the most effective intervention — partial improvement typically occurs after avoidance, but complete resolution requires early removal before remodeling occurs.

This article is for informational purposes only. Consult a qualified healthcare professional before making any health decisions.